Modality
Cell Therapy
MOA
GLP-1/GIP
Target
IL-13
Pathway
Amyloid
MDSIPF
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
May 2019
→ Sep 2027
Phase 2Current
NCT07866175
1,235 pts·IPF
2021-04→2026-05·Completed
NCT04396606
2,762 pts·MDS
2019-05→2027-09·Not yet recruiting
3,997 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-262mo awayPh3 Readout· IPF
2027-09-261.5y awayPh3 Readout· MDS
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Not yet…
P2/3
Complet…
Catalysts
Ph3 Readout
2026-05-26 · 2mo away
IPF
Ph3 Readout
2027-09-26 · 1.5y away
MDS
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07866175 | Phase 2/3 | IPF | Completed | 1235 | VA |
| NCT04396606 | Phase 2/3 | MDS | Not yet recr... | 2762 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Elrarapivir | Iovance | Phase 2 | IL-13 |